Results 21 to 30 of about 3,067,072 (318)
Selective JAK-Inhibitors in Spondyloarthritis [PDF]
Mediterranean Journal of RheumatologyAs our research interest and knowledge increases in the field of Spondyloarthritis, new aspects also emerge as regards to their therapeutic approach. JAK inhibitors (JAKi) are a relatively new treatment option, aiming molecules in the JAK-STAT pathway, which has a leading role in the pathophysiology of both Psoriatic Arthritis and Axial ...
Vassilakis, Konstantinos D. +3 more
openaire +4 more sources
MedicinaBackground and Objectives: Atopic dermatitis is a chronic inflammatory skin disorder with a significant burden on patients’ quality of life. This systematic review aims to evaluate the restoration of skin barrier abnormalities with interleukin-4 ...
Isidora Chatzigeorgiou +4 more
doaj +3 more sources
Indian Journal of Dermatology, Venereology and Leprology, 2023 The Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway is a key regulatory signaling system for cellular proliferation, differentiation, and apoptosis. In addition, JAK signaling pathway plays critical roles in orchestrating immune response through its interactions with the cytokine receptors and the transcriptions ...
Siba P, Raychaudhuri +1 more
openaire +2 more sources
The JAK-STAT Pathway and the JAK Inhibitors [PDF]
Journal of Clinical Research in Dermatology, 2020 Dozens of cytokines that bind Type I and Type II receptors use the Janus Kinases (JAK) and the Signal Transducer and Activator of Transcription (STAT) proteins pathway for intracellular signaling, orchestrating hematopoiesis, inducing inflammation, and controlling the immune response.
Ana Paula Galli Sanchez +2 more
openaire +1 more source
JAK inhibitors for the treatment of palmoplantar pustulosis: a narrative review. [PDF]
Drugs ContextBackground: Palmoplantar pustulosis (PPP) is a chronic, relapsing skin condition characterized by sterile, pruritic pustules on erythematous, thickened skin of the palms and soles.
Henriques Dos Santos B +3 more
europepmc +2 more sources
Janus kinase inhibitors in autoimmune bullous diseases
Frontiers in Immunology, 2023 Autoimmune bullous disease (AIBD) is a severe skin disorder caused by autoantibodies that target intercellular or cell-matrix adhesion proteins.
Dawei Huang +9 more
doaj +1 more source
JAK Inhibitors in Rheumatoid Arthritis
European Medical Journal Allergy & Immunology, 2022 JAK inhibitors (JAKi) are targeted, small-molecule, disease-modifying therapies that are the newest class of treatments to emerge for the management of rheumatoid arthritis (RA) and the first oral disease-modifying anti-rheumatic drugs (DMARD) to ...
Kathryn Biddle +2 more
doaj +1 more source
JAK inhibitors in autoinflammation [PDF]
Journal of Clinical Investigation, 2018 Interferonopathies are a subset of autoinflammatory disorders with a prominent type I IFN gene signature. Treatment of these patients has been challenging, given the lack of response to common autoinflammatory therapeutics including IL-1 and TNF blockade.
Hal M, Hoffman, Lori, Broderick
openaire +2 more sources
A Review on the Safety of Using JAK Inhibitors in Dermatology: Clinical and Laboratory Monitoring
Dermatologic Therapy, 2023 Janus kinase (JAK) inhibitors are disease-modifying agents with efficacy in treating a spectrum of burdensome dermatologic conditions. The US Food and Drug Administration (FDA) recently placed a black box warning on this class of medications due to ...
Christeen Samuel +3 more
semanticscholar +1 more source
JAK Inhibitors in the Treatment of Atopic Dermatitis.
Journal of Allergy and Clinical Immunology, 2021 Atopic dermatitis is a chronic inflammatory skin disorder associated with heterogenous presentation and often immense patient burden. Safe, targeted treatment options are currently limited.
Luiza de Bortolli Nogueira +5 more
semanticscholar +1 more source